Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
RESEARCH TOOLSreports
Holding AU:ATX?
Track your performance easily
ATX Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.05 - AU$0.18
Previous CloseAU$0.09
Volume240.09K
Average Volume (3M)994.70K
Market Cap
AU$32.24M
Enterprise ValueAU$19.73M
Total Cash (Recent Filing)AU$14.61M
Total Debt (Recent Filing)AU$2.10M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Nov 29, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares OutstandingN/A
10 Day Avg. Volume2,208,693
30 Day Avg. Volume994,704
Standard Deviation0.18
R-Squared0.12
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Amplia Therapeutics Ltd. News
PremiumCompany Announcements
Amplia Therapeutics Sets EGM for Shareholder Approvals
PremiumCompany Announcements
Amplia Therapeutics Partners with Next&Bio for Cancer Research
PremiumCompany Announcements
Amplia Therapeutics Shareholding Update by Platinum Asset
PremiumCompany Announcements
Amplia Therapeutics Completes $13M Share Allotment
PremiumCompany Announcements
Amplia Therapeutics Lists New Shares on ASX
PremiumCompany Announcements
Amplia Therapeutics to Issue New Securities on ASX
PremiumCompany Announcements
Amplia Therapeutics Boosts Stock Confidence with Underwritten OfferPremiumCompany Announcements
Amplia Therapeutics Announces $4.9M Capital Raising PlanOptions Prices
Currently, No data available
---
Ownership Overview
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.17 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 29, 2024 which is in 7 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on May 30, 2024. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.017.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 358,243,260 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.557%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
---
Amplia Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ATX Sentiment 96%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.75%
12-Months-Change
Fundamentals
Return on Equity
-32.71%
Trailing 12-Months
Asset Growth
-22.61%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
---
Technical Analysis
Anixa Biosciences
―
TRACON Pharmaceuticals
―
Immutep
―
Cellectar Biosciences
―
Amplia Therapeutics Ltd.
―
---